Precipio, Inc. (PRPO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0800 |
| Open | 1.0600 |
| Bid | 1.0700 x 1300 |
| Ask | 1.0800 x 900 |
| Day's Range | 1.0500 - 1.0900 |
| 52 Week Range | 0.9100 - 4.6500 |
| Volume | |
| Avg. Volume | 270,662 |
| Market Cap | 24.298M |
| Beta (5Y Monthly) | 2.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3570 |
| Earnings Date | Mar 29, 2022 - Apr 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Simply Wall St.
When Will Precipio, Inc. (NASDAQ:PRPO) Breakeven?
We feel now is a pretty good time to analyse Precipio, Inc.'s ( NASDAQ:PRPO ) business as it appears the company may be...
- GlobeNewswire
Precipio Signs First IV-Cell Customer Agreement
Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potentialNEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida, has completed its validation of Precipio’s proprietary IV-Cell® culture media, and will adopt the product for use in its clinical cytogenetics laboratory. The adoption of IV-Cell by industry leader AON demonstr
- GlobeNewswire
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College, organized by publication Dark Daily, the premier laboratory conference, held April 26th through 28th in New Orleans. Gathering for the first time in person after two years, laboratory executives will meet at the conference to shar
